Maintaining and growing KOL relationships in pandemic lockdown At a stroke, the COVID-19 pandemic shut down MSL's principal KOL engagement channels. With face-to-face interactions on hold, MSLs have turned to...

How far has pharma come, and what does it still need to do, to realize the full benefits of digital technology across its business? The COVID-19 pandemic may have spurred rapid expansion in the use of digital tools but...

ICER is here to stay so how best can industry engage for its benefit? The Institute for Clinical and Economic Review (ICER) is gaining a growing reputation with US payers. While ICER's drug assessments are advisory, and...

Which KPI's should pharma be using to assess the success of its digital technology investments? The Covid-19 pandemic is fundamentally changing working practice and driving immediate expansion of digital solutions. But...

The strategies that are promoting wider use of biosimilars Payers are highly motivated to realise the cost savings of biosimilars, but what strategies are they using to reassure and encourage physicians and patients?...

Embedding digital patient engagement throughout the patient journey Pharma companies have made good progress with digital delivery within innovative patient support programs—but there is still significant scope to...

Pharma challenged to rethink its market access strategies While the promise of cell and gene therapy (C&GT) to deliver enduring or even curative treatments is welcomed there is no long-term market experience and...

Which digital health technologies are exciting payers? How and where can digital health technology improve patient outcomes and save payers money? Across the digital health field there are hundreds of applications...